CLSD - Clearside Biomedical, Inc.
IEX Last Trade
0.9558
0.006 0.607%
Share volume: 3,262
Last Updated: Fri 27 Dec 2024 08:30:04 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$0.95
0.01
0.61%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
| Report Date | 2022-05-12 | 2022-08-12 | 2022-11-09 | 2023-03-14 | 2023-05-12 | 2023-08-14 | 2023-11-13 | 2024-03-12 | |
| Assets | |||||||||
| Total Assets | 36.059 M | 30.746 M | 55.685 M | 51.303 M | 44.695 M | 39.185 M | 34.420 M | 34.018 M | |
| Current Assets | 35.274 M | 29.989 M | 54.862 M | 49.401 M | 42.567 M | 36.107 M | 30.815 M | 30.123 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 902.000 K | 833.000 K | 1.358 M | 1.143 M | 1.148 M | 847.000 K | 1.131 M | 1.033 M | |
| Short Term Investments | 902.000 K | 833.000 K | 1.358 M | 1.143 M | 1.148 M | 847.000 K | 1.131 M | 1.033 M | |
| Total Receivables | 0.000 | 123.000 K | 123.000 K | 0.000 | 0.000 | 255.000 K | 882.000 K | 170.000 K | |
| Current Cash | 34.372 M | 29.033 M | 53.381 M | 48.258 M | 41.419 M | 35.005 M | 28.802 M | 28.920 M | |
| Total Non-current Assets | 785.000 K | 757.000 K | 823.000 K | 1.902 M | 2.128 M | 3.078 M | 3.605 M | 3.895 M | |
| Property Plant Equipment | 301.000 K | 321.000 K | 437.000 K | 755.000 K | 1.041 M | 2.052 M | 2.642 M | 2.996 M | |
| Other Assets | 324.000 K | 276.000 K | 226.000 K | 1.147 M | 1.087 M | 1.026 M | 963.000 K | 899.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 36.059 M | 30.746 M | 55.685 M | 51.303 M | 44.695 M | 39.185 M | 34.420 M | 34.018 M | |
| Total liabilities | 4.356 M | 5.498 M | 37.139 M | 40.696 M | 41.995 M | 44.158 M | 47.269 M | 49.930 M | |
| Total current liabilities | 4.156 M | 5.393 M | 5.204 M | 5.783 M | 4.984 M | 5.274 M | 5.835 M | 6.813 M | |
| Accounts Payable | 1.396 M | 2.644 M | 1.739 M | 1.050 M | 1.594 M | 1.886 M | 1.867 M | 2.205 M | |
| Other liabilities | 0.000 | 0.000 | 31.935 M | 33.977 M | 36.144 M | 38.088 M | 40.710 M | 42.468 M | |
| Current long term debt | 391.000 K | 395.000 K | 407.000 K | 349.000 K | 356.000 K | 359.000 K | 362.000 K | 364.000 K | |
| Long term debt | 200.000 K | 105.000 K | 0.000 | 936.000 K | 867.000 K | 796.000 K | 724.000 K | 649.000 K | |
| Other liabilities | 0.000 | 0.000 | 31.935 M | 33.977 M | 36.144 M | 38.088 M | 40.710 M | 42.468 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 31.703 M | 25.248 M | 18.546 M | 10.607 M | 2.700 M | -4.973 M | -12.849 M | -15.912 M | |
| Common stock | 60.064 M | 60.150 M | 60.189 M | 60.416 M | 61.169 M | 61.655 M | 61.984 M | 62.420 M | |
| Retained earnings | -263.135 M | -270.948 M | -278.775 M | -288.438 M | -297.718 M | -306.824 M | -316.091 M | -320.923 M |